ad image

Orphan Drug Designation

1 / 1
APR Applied Pharma Research s.a.
PR-M12-19-NI-018

FDA Grants Orphan Drug Designation to Epidermolysis Bullosa Treatment

APR Applied Pharma Research s.a.

PA1853Dec 12, 2019
Dynacure
Orphan Drug Designation

Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'

Dynacure

PR-M08-19-NI-039Aug 14, 2019
An Expanding Orphan Drug Market
Orphan Drug Development

An Expanding Orphan Drug Market

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

PAP-Q2-2019-NI-001May 24, 2019
Navigating the Road to Successful Orphan Drug Commercialization and Launch
Orphan Drug Development

Navigating the Road to Successful Orphan Drug Commercialization and Launch

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

PAP-Q2-2019-NI-003May 24, 2019
Cholangiocarcinoma Drug Receives Orphan Drug Designation from FDA
Orphan Drug

Cholangiocarcinoma Drug Receives Orphan Drug Designation from FDA

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M03-19-NI-003Mar 05, 2019
Sutro Biopharma, Inc.
Multiple Myeloma

Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Sutro Biopharma, Inc.

PR-M10-18-NI-049Oct 15, 2018
OBI Pharma
Orphan Drug Designation

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

OBI Pharma

PR-M09-18-NI-082Sep 26, 2018
Sirnaomics, Inc.
FDA Approval

Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma

Sirnaomics, Inc.

PR-M09-18-NI-062Sep 20, 2018
Martin Pharmaceuticals
Drug Designation

Martin Pharmaceuticals’ LIVANTRA™ Receives FDA Orphan Drug Designation in Second Indication

Martin Pharmaceuticals

PR-M09-18-NI-033Sep 13, 2018
Alector
Drug Designation

Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia

Alector

PR-M08-18-NI-080Aug 21, 2018
Alteogen
FDA Approval

Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer

Alteogen

PR-M08-18-NI-052Aug 14, 2018
1 / 1